Cao Longxiang Family

Age: 68 — Cao Longxiang is in the later stages of his active business career, which may influence strategic decisions around succession, capital preservation, and legacy building.

Residence: Taixing, China — A city in Jiangsu Province, known for its industrial base and proximity to Shanghai. This location may offer logistical advantages for pharmaceutical distribution and access to regional talent.

Citizenship: China — His domestic status aligns with his business focus and regulatory environment. Chinese billionaires often face unique challenges related to capital controls, currency convertibility, and cross-border investment restrictions.

Marital Status: Married — While personal life details are limited, family involvement in the business (via his son) suggests a strong familial governance structure, which is common in Chinese family-owned enterprises.

Professional Background: Prior experience in a cement factory and military service likely instilled operational discipline, hierarchical management, and risk assessment skills — all valuable in scaling a complex, regulated industry like pharmaceuticals.

Business Evolution: Transitioning a machinery company into a pharmaceutical giant required strategic rebranding, asset reallocation, and regulatory navigation — a testament to Cao’s adaptability and long-term vision.

Succession Planning: Appointing his son as vice chairman indicates a deliberate effort to ensure continuity. Family succession in Chinese businesses can be both a strength (alignment of interests, cultural cohesion) and a risk (governance challenges, talent gaps).

Market Context: China’s pharmaceutical sector is undergoing rapid transformation — with increased emphasis on innovation, quality control, and international expansion. Cao’s company, with its dual focus on Western and TCM products, is positioned to benefit from both domestic demand and potential export opportunities.

As of April 1, 2025, Cao Longxiang’s net worth is estimated at $1.4 billion, placing him at #1448 globally on the Billionaires list. This valuation is derived primarily from his controlling stake — more than 60% — in Hubei Jumpcan Pharmaceutical, a publicly traded company listed on the Shanghai Stock Exchange. The company’s market capitalization, stock price fluctuations, and dividend policies directly influence Cao’s net worth. Unlike many billionaires whose wealth is tied to private equity or venture-backed startups, Cao’s fortune is largely transparent and subject to daily market movements, though private holdings or family assets not disclosed in public filings may add to his total net worth.

His ranking has shifted over time: in 2020, he was ranked #241 on the China Rich List, indicating a significant drop in relative standing over five years. This decline may reflect broader market corrections in China’s pharmaceutical sector, regulatory pressures, or changes in investor sentiment toward domestic drug manufacturers. It may also reflect a recalibration of wealth metrics by , which periodically adjusts methodology to account for currency fluctuations, asset liquidity, and ownership structures.

Ownership concentration above 60% suggests Cao retains significant control over corporate strategy, capital allocation, and executive appointments. This level of control is uncommon in Western public companies but not unusual in China, where founder-led firms often maintain dominant voting power through dual-class shares or family trusts. His son, Cao Fei, serving as vice chairman, further reinforces the family’s grip on governance and succession planning. The company’s dual focus on Western and traditional Chinese medicine positions it to capture both modern and culturally rooted healthcare markets — a strategic advantage in a country where TCM remains deeply embedded in public health infrastructure.

Valuation of publicly traded stakes like Cao’s is typically calculated by multiplying the number of shares held by the current stock price. However, this method assumes full liquidity, which is rarely the case for controlling shareholders. Large blocks of shares cannot be sold without depressing the stock price, meaning the “paper wealth” reported by may overstate the actual liquid value available to Cao. Additionally, private assets — real estate, investments in unlisted firms, or offshore holdings — are not captured in this figure unless disclosed in regulatory filings.

China’s pharmaceutical industry has undergone rapid consolidation and regulatory tightening in recent years, particularly around drug pricing, patent enforcement, and clinical trial standards. These factors directly impact Hubei Jumpcan’s profitability and, by extension, Cao’s net worth. The company’s ability to navigate these headwinds — through innovation, cost control, or strategic acquisitions — will determine whether his wealth stabilizes or continues to erode in coming years.

Cao Longxiang’s wealth trajectory reflects a classic Chinese entrepreneurial arc: from state-sector employment to private-sector dominance, culminating in a publicly traded empire. His net worth was not publicly tracked before 2020, when he entered the China Rich List at #241. This suggests his wealth accumulation accelerated significantly in the 2010s, coinciding with his acquisition of control over Hubei Jumpcan Pharmaceutical in 2013. Prior to that, the company operated under a different name — Hubei Hongcheng General Machinery — and was likely a state-owned or state-influenced entity. Cao’s takeover marked a pivotal shift from industrial manufacturing to pharmaceuticals, a sector with higher margins and greater scalability.

The 2013 acquisition was likely structured through a combination of share purchases, asset swaps, and possibly government approvals, given China’s regulatory environment for state-owned enterprises. By taking control, Cao effectively transformed a machinery company into a pharmaceutical powerhouse, leveraging his industry connections and operational experience. The company’s rebranding to Hubei Jumpcan Pharmaceutical signaled a strategic pivot, aligning with national priorities around healthcare modernization and self-reliance in medicine production.

Between 2013 and 2020, Cao’s net worth likely grew rapidly as the company expanded its product portfolio, secured regulatory approvals, and benefited from China’s rising healthcare spending. The 2020 ranking at #241 on the China Rich List implies a net worth in the multi-billion dollar range at that time — likely exceeding $3 billion, given the threshold for that ranking. However, by 2025, his global ranking had slipped to #1448, suggesting either a decline in absolute wealth or a surge in global billionaire numbers outpacing his growth.

Several factors may explain this shift. First, China’s pharmaceutical sector faced increased price controls and anti-corruption campaigns targeting drug distributors and manufacturers. Second, the global pandemic may have disrupted supply chains and altered demand patterns, affecting profitability. Third, investor sentiment toward Chinese equities cooled in the early 2020s due to regulatory crackdowns and geopolitical tensions, leading to broader market declines. These headwinds likely impacted Hubei Jumpcan’s stock performance, reducing the market value of Cao’s holdings.

Despite these challenges, Cao’s continued control of over 60% of the company suggests he retains significant influence and long-term confidence in the business. His son’s role as vice chairman indicates a deliberate succession plan, which may help stabilize investor confidence and ensure continuity. The company’s dual focus on Western and traditional Chinese medicine may also provide a hedge against regulatory or market volatility — TCM products often face less stringent pricing controls and enjoy strong domestic demand.

Looking ahead, Cao’s wealth will depend on Hubei Jumpcan’s ability to innovate, expand internationally, and adapt to evolving regulatory landscapes. The company’s public listing provides transparency but also exposes it to market pressures that private firms can avoid. If Cao can maintain control while driving growth, his net worth may rebound; if not, further declines are possible. The path forward will likely involve strategic partnerships, R&D investments, and possibly diversification into adjacent healthcare sectors such as biologics or digital health.

Cao Longxiang operates in the global pharmaceutical sector alongside other self-made billionaires whose fortunes are rooted in domestic healthcare markets:

• Dilip Shanghvi & family — Indian pharmaceutical magnate and founder of Sun Pharmaceutical Industries, one of the world’s largest generic drug makers.
• Pankaj Patel — Chairman of Zydus Lifesciences, another major Indian pharmaceutical company with a strong presence in generics and branded formulations.
• Setiawan family — Indonesian pharmaceutical entrepreneurs behind Kalbe Farma, a leading healthcare group in Southeast Asia.
• Sun Piaoyang — Chinese billionaire and chairman of Jiangsu Hengrui Medicine, a major player in oncology and innovative drugs in China.

These peers share common traits: deep local market knowledge, regulatory navigation skills, and the ability to scale manufacturing while maintaining quality and compliance. Unlike many Western pharma giants that rely on R&D-driven innovation, these entrepreneurs often built empires through distribution, manufacturing efficiency, and strategic acquisitions — a model that aligns with Cao’s trajectory.

Cao Longxiang’s early life reflects the typical trajectory of many Chinese entrepreneurs who rose through the ranks of state-owned enterprises before transitioning to private-sector leadership. Born in China, he served in the Chinese military — a common path for men of his generation, providing discipline, networking opportunities, and exposure to organizational structures. After his military service, he entered the industrial sector, working as a manager at a cement factory. This role likely honed his operational and managerial skills, giving him a foundation in logistics, supply chain management, and labor relations — all critical for later success in pharmaceutical manufacturing.

His move from cement to pharmaceuticals was not a direct leap but rather a strategic pivot, likely facilitated by connections, industry shifts, or personal ambition. The pharmaceutical sector in China has long been dominated by state-owned enterprises, but the 1990s and 2000s saw increasing privatization and consolidation, creating opportunities for capable managers to take control of underperforming assets. Cao’s background in heavy industry may have given him an edge in understanding the complexities of large-scale manufacturing — a skill directly transferable to pharmaceutical production, which requires strict quality control, regulatory compliance, and efficient logistics.

Little is publicly disclosed about his education, family background, or early entrepreneurial ventures. This lack of detail is common among Chinese billionaires whose rise occurred during periods of rapid economic transformation, where personal histories were often overshadowed by corporate achievements. His marriage and family life remain private, though the involvement of his son, Cao Fei, in the company suggests a strong family legacy and a deliberate succession plan. The fact that his son holds a senior position indicates that Cao has invested in grooming the next generation, a practice increasingly common among Chinese business dynasties.

His early career in the military and cement industry may also reflect the broader socioeconomic context of his generation. Many Chinese entrepreneurs of his age cohort began in state-run enterprises, where loyalty, discipline, and bureaucratic navigation were valued. Transitioning to the private sector required not just business acumen but also political savvy — the ability to navigate regulatory environments, secure approvals, and build relationships with local governments. These skills likely played a crucial role in his eventual takeover of Hubei Jumpcan Pharmaceutical in 2013.

While details of his childhood, education, and early motivations remain undisclosed, his career path suggests a pragmatic, incremental approach to wealth creation. Rather than founding a startup from scratch, he leveraged existing assets and industry knowledge to build a pharmaceutical empire. This model — acquiring and revitalizing underperforming state-owned enterprises — has been a hallmark of Chinese capitalism in the post-reform era, and Cao’s success exemplifies its potential for generating significant wealth.

Cao Longxiang’s path to wealth is a textbook case of Chinese entrepreneurial evolution: from state-sector manager to controlling shareholder of a publicly traded pharmaceutical giant. His journey began not in finance or technology but in heavy industry — specifically, as a manager at a cement factory. This role provided him with foundational skills in operations, logistics, and labor management, all of which would prove invaluable in the pharmaceutical sector, where precision, scale, and regulatory compliance are paramount. His service in the Chinese military further instilled discipline and organizational acumen, traits that likely aided his transition into corporate leadership.

The pivotal moment in his career came in 2013, when he took control of Hubei Hongcheng General Machinery — a company that had gone public in 2001 but was likely underperforming or misaligned with market demands. By acquiring control, Cao effectively repositioned the company as Hubei Jumpcan Pharmaceutical, signaling a strategic shift from industrial machinery to healthcare. This transformation was not merely a rebranding but a fundamental restructuring, likely involving asset divestitures, management overhauls, and product line expansions. The decision to focus on both Western and traditional Chinese medicine was astute, allowing the company to serve diverse market segments and mitigate regulatory risks.

His ownership stake of more than 60% suggests he either purchased shares directly, executed a leveraged buyout, or negotiated a complex restructuring with existing shareholders — possibly including local governments or state-owned entities. In China, such transactions often require regulatory approvals and political capital, indicating that Cao had built significant influence by this point. The fact that he retained control after the company’s public listing is notable, as many Chinese entrepreneurs dilute their stakes during IPOs. His continued dominance suggests a long-term vision and confidence in the company’s growth potential.

The company’s dual focus on Western and traditional Chinese medicine is a strategic advantage. Western pharmaceuticals offer higher margins and global scalability, while TCM products benefit from cultural acceptance, government support, and less stringent pricing controls. This hybrid model allows Hubei Jumpcan to diversify its revenue streams and hedge against market volatility. Additionally, China’s aging population and rising healthcare spending provide a tailwind for pharmaceutical demand, positioning the company for sustained growth.

His son, Cao Fei, serving as vice chairman, indicates a deliberate succession plan. This is increasingly common among Chinese business families, where wealth preservation and continuity are prioritized over rapid expansion. The involvement of the next generation may also signal a shift toward more modern corporate governance practices, including transparency, investor relations, and strategic planning — all critical for maintaining public market confidence.

Looking ahead, Cao’s wealth will depend on Hubei Jumpcan’s ability to innovate, expand internationally, and adapt to evolving regulatory landscapes. The company’s public listing provides transparency but also exposes it to market pressures that private firms can avoid. If Cao can maintain control while driving growth, his net worth may rebound; if not, further declines are possible. The path forward will likely involve strategic partnerships, R&D investments, and possibly diversification into adjacent healthcare sectors such as biologics or digital health.

Cao Longxiang’s empire centers on Hubei Jumpcan Pharmaceutical, a vertically integrated player in China’s domestic pharmaceutical market with dual expertise in Western and traditional Chinese medicine (TCM). This hybrid model grants the company a unique competitive edge in a market where regulatory and consumer preferences increasingly favor TCM integration. With over 60% ownership, Cao maintains tight control, enabling rapid decision-making but also concentrating risk within a single entity. The company’s origins as Hubei Hongcheng General Machinery—a state-linked industrial firm—highlight a strategic pivot from heavy industry to high-margin healthcare, a transformation emblematic of China’s broader economic realignment. The empire’s durability hinges on its ability to navigate China’s evolving regulatory landscape, particularly as the National Medical Products Administration (NMPA) tightens oversight on TCM efficacy and safety.

Cao Longxiang’s leadership reflects a blend of military discipline and industrial pragmatism. His background as a cement factory manager and former military service suggests a top-down, execution-focused management style. The appointment of his son, Cao Fei, as vice chairman signals a dynastic succession model common in Chinese private enterprises, but also raises governance concerns around board independence and meritocracy. While this structure ensures continuity, it may limit innovation and external oversight. Cao’s hands-on control over operations and capital allocation underscores a founder-centric model that prioritizes stability over agility—a double-edged sword in an industry increasingly driven by R&D and global partnerships.

Capital allocation at Hubei Jumpcan appears heavily concentrated in domestic expansion and vertical integration, with limited public evidence of international diversification or high-risk R&D bets. The company’s public listing since 2001 and Cao’s 60% stake suggest a preference for retained earnings and internal funding over external capital markets. This strategy reduces leverage risk but may constrain growth in a capital-intensive sector. The lack of disclosed M&A activity or overseas investments indicates a conservative posture, possibly reflecting regulatory caution or a focus on consolidating domestic market share. However, this insularity exposes the empire to macroeconomic shocks and policy shifts within China’s healthcare system.

Key risks include regulatory exposure, as China’s pharmaceutical sector faces intensified scrutiny over TCM standardization and pricing controls. Hubei Jumpcan’s dual focus on Western and traditional medicine may trigger compliance challenges if regulators demand stricter clinical validation for TCM products. Concentration risk is acute: over 60% ownership by Cao and family creates vulnerability to personal or political events. Geopolitical risk is moderate—while not directly targeted by U.S. sanctions, the company’s reliance on domestic supply chains and state-linked origins could draw scrutiny in a decoupling scenario. Reputational risk is latent; any safety or efficacy scandal involving TCM products could trigger consumer backlash and regulatory penalties, given the sector’s sensitivity.

Public records show no significant philanthropic activity tied to Cao Longxiang or Hubei Jumpcan, a notable gap compared to peers like Sun Piaoyang or Dilip Shanghvi, who have established foundations or public health initiatives. This absence may reflect a private, family-centric approach to giving or a strategic choice to avoid public scrutiny. In China’s context, where corporate philanthropy is often tied to state-aligned social goals, the lack of visible charitable engagement could be perceived as a missed opportunity to build social capital or mitigate regulatory risk. However, it also avoids the reputational pitfalls of poorly managed or politicized giving.

Cao’s influence is largely indirect, rooted in the company’s scale and alignment with China’s healthcare priorities. As a major domestic pharma player, Hubei Jumpcan likely benefits from state procurement policies and TCM promotion initiatives, though no direct political appointments or lobbying disclosures are public. The company’s origins in a state-owned machinery firm and Cao’s military background may facilitate access to local government networks, but there is no evidence of national-level political engagement. Geopolitically, the firm’s domestic focus insulates it from U.S.-China tensions, but its reliance on state-aligned infrastructure and regulatory approval creates dependency on Beijing’s policy direction.

Cao Longxiang’s legacy is defined by transforming a state-industrial relic into a pharmaceutical powerhouse, embodying China’s transition from manufacturing to high-value services. His empire’s durability rests on its hybrid TCM-Western model, which taps into both cultural preference and regulatory tailwinds. However, the legacy’s sustainability is contingent on successful succession—Cao Fei’s role as vice chairman is a necessary but insufficient step. Without institutionalizing governance, diversifying capital allocation, or expanding internationally, the empire risks stagnation. The absence of public philanthropy or global brand-building further limits its aspirational legacy, positioning it as a regional powerhouse rather than a global innovator.

• Profile: Cao Longxiang & family (
• Company history: Hubei Hongcheng General Machinery to Hubei Jumpcan Pharmaceutical
• China’s National Medical Products Administration (NMPA) TCM regulations
• “Healthy China 2030” policy framework